



**Drug Name:** Breo Ellipta 50/25 mcg, fluticasone furoate/vilanterol 100/25 mcg and 200/25 mcg, fluticasone/salmeterol HFA 45/21 mcg, 115/21 mcg and 230/21 mcg, and Dulera 50-5 mcg, 100-5 mcg, 200-5 mcg

**Last Revision Date:** 06/2016, 4/2020, 5/2021, 7/2021, 6/2022, 5/2023, 12/2023, 03/2024

<b>Required Medical Information:</b>	The member has tried and failed a short acting/rescue albuterol inhaler, inhaled corticosteroid, or a generic/formulary no restriction ICS/LABA combination product (e.g., Wixela) within the past 90 days
<b>Coverage Duration:</b>	12 months
<b>Coding Logic for Step Therapy:</b>	Breo Ellipta 50/25 mcg, fluticasone furoate/vilanterol 100/25 mcg and 200/25 mcg, fluticasone/salmeterol 45/21mcg, 115/21 mcg and 230/21 mcg, or Dulera will pay if there is a paid claim in the PBM's system for a short acting albuterol inhaler, inhaled corticosteroid, or a generic/formulary no restriction ICS/LABA combination product within the past 365 days